Market open
iTeos Therapeutics/$ITOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Ticker
$ITOS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
173
ISIN
US46565G1040
Website
ITOS Metrics
BasicAdvanced
$291M
-
-$3.09
1.43
-
Price and volume
Market cap
$291M
Beta
1.43
52-week high
$18.70
52-week low
$4.80
Average daily volume
995K
Financial strength
Current ratio
14.133
Quick ratio
13.78
Long term debt to equity
0.646
Total debt to equity
0.897
Management effectiveness
Return on assets (TTM)
-14.54%
Return on equity (TTM)
-23.68%
Valuation
Price to revenue (TTM)
9.19
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-3.206
Growth
Earnings per share change (TTM)
-18.24%
3-year revenue growth (CAGR)
-58.71%
3-year earnings per share growth (CAGR)
-26.31%
What the Analysts think about ITOS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.
ITOS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ITOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ITOS News
AllArticlesVideos
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewsWire·2 days ago
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·2 weeks ago
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for iTeos Therapeutics stock?
iTeos Therapeutics (ITOS) has a market cap of $291M as of May 15, 2025.
What is the P/E ratio for iTeos Therapeutics stock?
The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of May 15, 2025.
Does iTeos Therapeutics stock pay dividends?
No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next iTeos Therapeutics dividend payment date?
iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.
What is the beta indicator for iTeos Therapeutics?
iTeos Therapeutics (ITOS) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.